Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

Published:2013-12-19 Issue:1 Volume:29 Page:158-165
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Keaveny Tony M¹²,McClung Michael R³,Genant Harry K⁴⁵,Zanchetta Jose R⁶,Kendler David⁷,Brown Jacques P⁸,Goemaere Stefan⁹,Recknor Chris¹⁰,Brandi Maria L¹¹,Eastell Richard¹²,Kopperdahl David L²,Engelke Klaus¹³¹⁴,Fuerst Thomas⁵,Radcliffe Hoi‐Shen¹⁵,Libanati Cesar¹⁶

Affiliation:

1. University of California BerkeleyBerkeleyCAUSA

2. O.N. DiagnosticsBerkeleyCAUSA

3. Oregon Osteoporosis CenterPortlandORUSA

4. University of California San FranciscoCAUSA

5. Synarc Inc.San FranciscoCAUSA

6. IDIMBuenos AiresArgentina

7. University of British ColumbiaVancouverCanada

8. CHU de Québec Research CentreQuébecCanada

9. Ghent University HospitalGhentBelgium

10. United Osteoporosis CentersGainesvilleGAUSA

11. University of FlorenceFlorenceItaly

12. University of SheffieldSheffieldUK

13. Synarc Inc.HamburgGermany

14. Institute of Medical PhysicsUniversity of Erlangen, ErlangenGermany

15. Amgen Ltd.CambridgeUK

16. Amgen Inc.Thousand OaksCAUSA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.2024

Reference59 articles.

1. Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo

2. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

3. Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function*

4. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

5. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explainable machine‐learning‐based prediction of QCT/FEA‐calculated femoral strength under stance loading configuration using radiomics features;Journal of Orthopaedic Research;2024-08-25

2. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate;Journal of Bone and Mineral Research;2024-02-15

3. Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study;Journal of Endocrinological Investigation;2024-01-09

4. Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease;Metastatic Bone Disease;2024

5. Relative Effects of Radiation‐Induced Changes in Bone Mass, Structure, and Tissue Material on Vertebral Strength in a Rat Model;Journal of Bone and Mineral Research;2023-06-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3